Shield Therapeutics (GB:STX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shield Therapeutics has completed recruitment for its Phase 3 study in China, aimed at filing an NDA for ACCRUFeR®, a treatment for iron deficiency in patients with IBD. Meanwhile, the company reports strong sales of ACCRUFeR® in October, maintaining their aim to achieve a revenue target of $31.5 million for 2024. With promising market performance and strategic partnerships, Shield is poised for significant growth in the iron deficiency market.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.